The angiogenic factors CXCL8 and VEGF in breast cancer: regulation by an array of pro-malignancy factors

被引:52
作者
Azenshtein, E
Meshel, T
Shina, S
Barak, N
Keydar, I
Ben-Baruch, A [1 ]
机构
[1] Tel Aviv Univ, George S Wise Fac Life Sci, Dept Cell Res & Immunol, IL-69978 Tel Aviv, Israel
[2] Tel Aviv Sourasky Med Ctr, Dept Oncol, IL-64239 Tel Aviv, Israel
关键词
breast cancer; CCL2; CCL5; CXCL8; EGF; hormones; VEGF;
D O I
10.1016/j.canlet.2004.05.024
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The regulation of secretion of the angiogenic factors CXCL8 and Vascular Endothelial Growth Factors (VEGF) was determined in breast tumor cells and in monocytic cells (as host cells that contribute to breast cancer). CXCL8 secretion, and partly the secretion of VEGF, were up-regulated in monocytic cells, but not in breast tumor cells, by the CC chemokines CCL5 and CCL2. EGF potently up-regulated CXCL8 secretion by breast tumor cells, and its effect was promoted by a consecutive treatment of the cells by estrogen and progesterone. These findings provide evidence for a complex set of pro-malignancy factors that may control the expression of angiogenic mediators at breast tumor sites. (C) 2004 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:73 / 86
页数:14
相关论文
共 77 条
[1]   The CXC chemokine receptor 2, CXCR2, is the putative receptor for ELR+ CXC chemokine-induced angiogenic activity [J].
Addison, CL ;
Daniel, TO ;
Burdick, MD ;
Liu, H ;
Ehlert, JE ;
Xue, YY ;
Buechi, L ;
Walz, A ;
Richmond, A ;
Strieter, RM .
JOURNAL OF IMMUNOLOGY, 2000, 165 (09) :5269-5277
[2]   A dual role for tumor-derived chemokine RANTES (CCL5) [J].
Adler, EP ;
Lemken, CA ;
Katchen, NS ;
Kurt, RA .
IMMUNOLOGY LETTERS, 2003, 90 (2-3) :187-194
[3]   A deletion mutant of heregulin increases the sensitivity of breast cancer cells to chemotherapy without promoting tumorigenicity [J].
Atlas, E ;
Bojanowski, K ;
Mehmi, I ;
Lupu, R .
ONCOGENE, 2003, 22 (22) :3441-3451
[4]  
Azenshtein E, 2002, CANCER RES, V62, P1093
[5]  
Badache A, 2001, CANCER RES, V61, P383
[6]   Inflammation and cancer: back to Virchow? [J].
Balkwill, F ;
Mantovani, A .
LANCET, 2001, 357 (9255) :539-545
[7]   EPIDERMAL GROWTH-FACTOR IN BREAST-CANCER [J].
BARKER, S ;
VINSON, GP .
INTERNATIONAL JOURNAL OF BIOCHEMISTRY, 1990, 22 (09) :939-945
[8]  
Belperio JA, 2000, J LEUKOCYTE BIOL, V68, P1
[9]  
Bendre MS, 2002, CANCER RES, V62, P5571
[10]   Activation of the unliganded estrogen receptor by EGF involves the MAP kinase pathway and direct phosphorylation [J].
Bunone, G ;
Briand, PA ;
Miksicek, RJ ;
Picard, D .
EMBO JOURNAL, 1996, 15 (09) :2174-2183